On November 8, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences (Press release, Atara Biotherapeutics, NOV 8, 2021, View Source [SID1234594704]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 5th Annual IO Next Summit
Fireside chat on Monday, November 15, 2021 at 9:45 a.m. EST

Stifel 2021 Virtual Healthcare Conference
Fireside chat on Monday, November 15, 2021 at 4:40 p.m. EST

Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside chat on Tuesday, November 30, 2021 at 10:05 a.m. EST

Live video webcasts will be available by visiting the Investor Events and Presentations section of atarabio.com. Archived replays will be available on the Company’s website for 30 days following the live webcasts.